These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 7867398)

  • 1. Clinical significance of measuring serum IL-6 activities in multiple myeloma. An analysis of 81 cases.
    Hou J; Kong XT
    Chin Med J (Engl); 1994 Nov; 107(11):868-9. PubMed ID: 7867398
    [No Abstract]   [Full Text] [Related]  

  • 2. [Clinical significance of soluble interleukin-2 receptor in multiple myeloma].
    Akimoto Y; Ishiyama T; Ueno H; Hino K; Tomoyasu S; Tsuruoka N
    Rinsho Ketsueki; 1995 Nov; 36(11):1247-51. PubMed ID: 8691563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic factors in multiple myeloma.
    Kyle RA
    Stem Cells; 1995 Aug; 13 Suppl 2():56-63. PubMed ID: 8520513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Influence of thalidomide on interleukin-6 and its transmission in multiple myeloma patients].
    Li J; Luo S; Hong W; Zhou Z; Zou W
    Zhonghua Zhong Liu Za Zhi; 2002 May; 24(3):254-6. PubMed ID: 12515619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between circulating interleukin-10 (IL-10) with interleukin-6 (IL-6) type cytokines (IL-6, interleukin-11 (IL-11), oncostatin M (OSM)) and soluble interleukin-6 (IL-6) receptor (sIL-6R) in patients with multiple myeloma.
    Urbańska-Ryś H; Wiersbowska A; Stepień H; Robak T
    Eur Cytokine Netw; 2000 Sep; 11(3):443-51. PubMed ID: 11022130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications.
    Lauta VM
    Cancer; 2003 May; 97(10):2440-52. PubMed ID: 12733143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical significance of serum vascular endothelial growth factor and interleukin-6 in multiple myeloma].
    Shen JK; Dong LH; Qi H; Zhang GS
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2005 Feb; 30(1):68-71. PubMed ID: 15871192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Multiple myeloma].
    Almazov VA; Afanasév BV; Podoltseva ZI
    Klin Med (Mosk); 1993; 71(2):5-10. PubMed ID: 8046926
    [No Abstract]   [Full Text] [Related]  

  • 9. [Assay of serum beta 2-microglobulin in patients with malignant hematologic diseases and its clinical significance].
    Zhong M; Liu W
    Hunan Yi Ke Da Xue Xue Bao; 1997; 22(3):277-8. PubMed ID: 9868137
    [No Abstract]   [Full Text] [Related]  

  • 10. Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activity.
    Alexandrakis MG; Passam FH; Sfiridaki A; Kandidaki E; Roussou P; Kyriakou DS
    Am J Hematol; 2003 Apr; 72(4):229-33. PubMed ID: 12666132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prognostic significance of beta-2-microglobulin in multiple myeloma].
    Podol'tseva EI; Morozova EV; Almazov VA
    Vopr Onkol; 1996; 42(4):32-5. PubMed ID: 8928455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The prognostic significance of the beta 2-microglobulin level of the blood serum in multiple myeloma patients].
    Lubo-Lesnichenko IF; Bessmel'tsev SS; Abdulkadyrov KM; Blinov MN; Stel'mashenko LV
    Ter Arkh; 1996; 68(10):28-31. PubMed ID: 9026938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High Th1/Th2 ratio in patients with multiple myeloma.
    Ogawara H; Handa H; Yamazaki T; Toda T; Yoshida K; Nishimoto N; Al-ma'Quol WH; Kaneko Y; Matsushima T; Tsukamoto N; Nojima Y; Matsumoto M; Sawamura M; Murakami H
    Leuk Res; 2005 Feb; 29(2):135-40. PubMed ID: 15607360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prognostic value of some biochemical and immunologic factors in the management of multiple myeloma].
    Abdulkadyrov KM; Stel'mashenko LV; Bessmel'tsev SS; Lubo-Lesnichenko IF; Sel'tser AV; Rozanova OE; Gubarenko NK; Bubnova LN; Mnuskina MM; Zhuchikhina AA; Blinov MN; Gritskevich NL
    Vopr Onkol; 1998; 44(3):304-9. PubMed ID: 9695777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum proinflammatory mediators at different periods of therapy in patients with multiple myeloma.
    Kuku I; Bayraktar MR; Kaya E; Erkurt MA; Bayraktar N; Cikim K; Aydogdu I
    Mediators Inflamm; 2005 Aug; 2005(3):171-4. PubMed ID: 16106104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Changes of serum interleukin 2 and soluble interleukin 2 receptor and their clinical significance in multiple myeloma].
    Wang Z; Li D; Yang J
    Zhonghua Zhong Liu Za Zhi; 1996 Nov; 18(6):439-41. PubMed ID: 9387297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Soluble interleukin-6 receptors in the serum in multiple myeloma].
    Scudla V; Kubalová D; Bacovský J; Lukes J; Vavrdová V
    Cas Lek Cesk; 1996 Nov; 135(22):719-22. PubMed ID: 8998823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytokines (IL-6, TNF-alpha, IL-1alpha) and soluble interleukin-2 receptor as serum tumor markers in multiple myeloma.
    Filella X; Blade J; Guillermo AL; Molina R; Rozman C; Ballesta AM
    Cancer Detect Prev; 1996; 20(1):52-6. PubMed ID: 8907203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Serum beta 2 microglobulin concentration in patients with multiple myeloma].
    Mendek-Czajkowska E
    Acta Haematol Pol; 1984; 15(3-4):161-5. PubMed ID: 6399429
    [No Abstract]   [Full Text] [Related]  

  • 20. Prognostic factors and staging systems of multiple myeloma:
    Tao ZF; Fu WJ; Yuan ZG; Wang DX; Chen YB; Hou J
    Chin Med J (Engl); 2007 Oct; 120(19):1655-8. PubMed ID: 17935664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.